Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Lei Shi

Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou 310022, PR China

Biography

Dr. Lei Shi is from the Department of Chemotherapy, at the Zhejiang Cancer Hospital, Dr. Lei Shi is a versatile writer and researcher that published extensively in specialized field. Dr. Lei Shi had 01 publications on his research field, and project on his research work" Irinotecan-Based Regimen as Second-Line Chemotherapy for Extensive-Stage Small Cell Lung Cancer".
Publications

Irinotecan-Based Regimen as Second-Line Chemotherapy for Extensive-Stage Small Cell Lung Cancer

Purpose: This study evaluates the clinical outcomes of extensive-stage small-cell lung cancer (SCLC) patients who received Irinotecan-based second-line chemotherapy after platinum-based first-line therapy, especially focused on efficacy and toxicity between single-agent and doublet chemotherapy. Patients and methods: We retrospectively reviewed 83... Read More»

Guoping Cheng and Lei Shi

Research Article: J Cancer Diagn 2016, 1: 102

DOI: 10.4172/2476-2253.1000102

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF Mobile Full Article

Relevant Topics
Top